Point72 Asset Management
CASC

Point72 Asset Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Point72 Asset Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-104,167
Closed -$1.02M – 931
2015
Q1 		$1.02M Sell
104,167
-16,012
-13% -$157K 0.01% 616
2014
Q4 		$1.37M Hold
120,179
– – 0.01% 579
2014
Q3 		$1.38M Buy
+120,179
New +$1.84M 0.01% 527

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's CASC Position: Q2 2015 in Review

Point72 Asset Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2015, closing a stake of 104,167 shares — an estimated $1.02M sold.

Point72 Asset Management first reported a position in CASC in Q3 2014 and held it in 3 quarters. The position peaked at $1.38M in Q3 2014. 100 funds tracked by Wall St. Rank hold CASC as of Q2 2015.

  • Point72 Asset Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Point72 Asset Management sold 104,167 Cascadian Therapeutics, Inc. shares in Q2 2015, an estimated $1.02M.
  • Point72 Asset Management first reported a position in Cascadian Therapeutics, Inc. in Q3 2014 and held it in 3 quarters.
  • Point72 Asset Management's Cascadian Therapeutics, Inc. position peaked at $1.38M in Q3 2014.
  • 100 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2015.

Based on Point72 Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.